Allena pharmaceutical companies have been a part of the healthcare industry for years.
From biologics to biopharmaceuticals, Allena has been a major player in the space.
Now, Allenes chief executive officer, John Fritsch, is joining the ranks of the big pharma giants in the biologies space.
Fritsch has been with Allena since 2016, and the company has been focused on making its products accessible to consumers.
Allena is using its existing relationships with the Food and Drug Administration (FDA) and the Food Innovation Alliance to explore ways to better target and market its products.
“The FDA is a key driver of the growth of the biopharma industry and our collaboration with them on the Biopharmarex initiative will help to build on this success,” Fritsh said in a statement.
“We have been working with the FDA for many years and we are excited to work with them to accelerate the adoption of innovative biopharming and other therapies for the disease.”
While Allena and Allena are currently focused on developing a drug specifically targeting the growth factor 1a protein in cancer, Fritsk said Allena could potentially work with the company on other products, too.
For example, Friesen told reporters at a conference last month that Allena would be interested in developing a cancer drug that targets the growth hormone that is involved in tumors’ growth.
“We’re working on a cancer treatment that targets growth hormone, and I think we’re looking to partner with Allen on that,” Frieseng said.
“It is an exciting time for biopharms,” said Dan Gaffney, CEO of Theranos, another startup in the pharma space that is being acquired by Allena.
“The opportunity to get Allena into business with Allene is really great for us and the other partners we have working with us.
It is really a no-brainer.”
Gaffney added that Allen could use the Allena acquisition to “drive more business” from the pharmas, which would be “a very positive step in driving innovation in the industry.”